NCT07174336 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07174336
Title	A Study of LY4064809 With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Eli Lilly and Company
Indications	breast cancer Her2-receptor negative breast cancer
Therapies	Letrozole + Palbociclib Fulvestrant + Palbociclib + STX-478 Anastrozole + Palbociclib Fulvestrant + Ribociclib + STX-478 Abemaciclib + Anastrozole + STX-478 Letrozole + Palbociclib + STX-478 Abemaciclib + Exemestane + STX-478 Letrozole + Ribociclib + STX-478 Abemaciclib + Fulvestrant + STX-478 Fulvestrant + Palbociclib Exemestane + Palbociclib Anastrozole + Palbociclib + STX-478 Abemaciclib + Letrozole + STX-478 Anastrozole + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Exemestane + Ribociclib + STX-478
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG

Additional content available in CKB BOOST